Shanghai MicroPort Endovascular MedTech Group Co Ltd
SSE:688016
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
79.81
194.56
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Shanghai MicroPort Endovascular MedTech Group Co Ltd
Shanghai MicroPort Endovascular MedTech Group Co Ltd
Accounts Payable
Shanghai MicroPort Endovascular MedTech Group Co Ltd
Accounts Payable Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accounts Payable | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Shanghai MicroPort Endovascular MedTech Group Co Ltd
SSE:688016
|
Accounts Payable
¥40.4m
|
CAGR 3-Years
31%
|
CAGR 5-Years
45%
|
CAGR 10-Years
N/A
|
|
|
Shandong Weigao Group Medical Polymer Co Ltd
HKEX:1066
|
Accounts Payable
¥4.7B
|
CAGR 3-Years
40%
|
CAGR 5-Years
37%
|
CAGR 10-Years
N/A
|
|
|
Eyebright Medical Technology Beijing Co Ltd
SSE:688050
|
Accounts Payable
¥49m
|
CAGR 3-Years
181%
|
CAGR 5-Years
201%
|
CAGR 10-Years
N/A
|
|
|
Autobio Diagnostics Co Ltd
SSE:603658
|
Accounts Payable
¥462.6m
|
CAGR 3-Years
31%
|
CAGR 5-Years
23%
|
CAGR 10-Years
N/A
|
|
|
Winner Medical Co Ltd
SZSE:300888
|
Accounts Payable
¥1.1B
|
CAGR 3-Years
15%
|
CAGR 5-Years
16%
|
CAGR 10-Years
N/A
|
|
|
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
|
Accounts Payable
¥127m
|
CAGR 3-Years
9%
|
CAGR 5-Years
15%
|
CAGR 10-Years
N/A
|
|
Shanghai MicroPort Endovascular MedTech Group Co Ltd
Glance View
Shanghai MicroPort Endovascular MedTech Group Co Ltd stands as a testament to China's burgeoning capabilities in the medtech landscape. The company was born from a vision to develop innovative solutions for treating cardiovascular diseases, which are among the leading causes of mortality worldwide. MicroPort Endovascular crafts specialized medical devices aimed at minimally invasive therapies, particularly in the vascular intervention domain. They produce stents, embolization coils, and vascular grafts—tools essential for intricate procedures like repairing damaged blood vessels or preventing life-threatening aneurysms. By aligning with cutting-edge technological advancements and rigorous clinical testing, MicroPort Endovascular has cemented its reputation as a trusted partner for medical professionals seeking reliable, effective, and technologically advanced instruments. MicroPort Endovascular’s revenue model is intrinsically linked to the global demand for cardiovascular solutions. With increasing incidences of cardiovascular diseases, partly due to lifestyle shifts and an aging population, the firm strategically positions itself in both domestic and international markets to capitalize on this demand. Their business operations span research and development, manufacturing, and distribution, allowing them to maintain control over quality and innovation while optimizing costs. Revenue flows from direct sales to hospitals and healthcare providers, as well as partnerships with distributors, ensuring widespread market penetration. Their continuous investment in R&D not only drives the introduction of new products but also enhances existing ones, thereby maintaining a competitive edge in a field where innovation is tantamount to success.
See Also
What is Shanghai MicroPort Endovascular MedTech Group Co Ltd's Accounts Payable?
Accounts Payable
40.4m
CNY
Based on the financial report for Dec 31, 2023, Shanghai MicroPort Endovascular MedTech Group Co Ltd's Accounts Payable amounts to 40.4m CNY.
What is Shanghai MicroPort Endovascular MedTech Group Co Ltd's Accounts Payable growth rate?
Accounts Payable CAGR 5Y
45%
Over the last year, the Accounts Payable growth was -4%. The average annual Accounts Payable growth rates for Shanghai MicroPort Endovascular MedTech Group Co Ltd have been 31% over the past three years , 45% over the past five years .
You don't have any saved screeners yet